Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ: APLS )

28.23 +0.05 (+0.18%)
Streaming Delayed Price Updated: 2:46 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Mid-Day Market Update: Crude Oil Rises Over 2%; Apellis Pharmaceuticals Shares Plunge
Midway through trading Friday, the Dow traded down 0.40% to 34,739.37 while the NASDAQ fell 0.06% to 15,238.92. The S&P also fell, dropping 0.21% to 4,483.84. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
41 Stocks Moving In Friday's Mid-Day Session
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic... 
Via Benzinga
Here's Why Iveric Bio Stock Is Rocketing Higher Today
Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program. 
Via The Motley Fool
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Analyst Ratings For Apellis Pharmaceuticals
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS... 
Via Benzinga
ISEE Stock: Why Rival Eye Drug Developer’s Disappointment Is a Boon to IVERIC bio
IVERIC bio (ISEE) stock is rocketing higher on Friday and there's a couple of catalysts behind the shares' positive movement today. 
Via InvestorPlace
Here's Why Apellis Pharmaceuticals Is Getting Hammered Today
Conflicting clinical trial results for the company's lead candidate are to blame. 
Via The Motley Fool
Why IVERIC Bio Shares Are Soaring Today
IVERIC Bio Inc (NASDAQ: ISEE) is trading significantly higher Friday after Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported results from its Phase 3 DERBY and OAKS studies... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views
Following the market opening Friday, the Dow traded down 0.15% to 34,827.04 while the NASDAQ rose 0.32% to 15,296.61. The S&P also rose, gaining 0.03% to 4,494.53. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Apellis Loses A Third Of Its Value; Are Its Mixed Results Enough To Win FDA OK?
Apellis Pharmaceuticals reported mixed results for an eye-disease treatment, leading APLS stock to crash on Friday. 
Via Investor's Business Daily
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Wells Fargo lowered the price target on General Motors Company (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers IVERIC bio (NASDAQ:ISEE) stock increased by 65.36% to $14.37 during Friday's pre-market session. The company's market cap stands at $1.4 billion. T2... 
Via Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4). T2... 
Via Benzinga
Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line
Apellis Pharmaceuticals Inc's (NASDAQ: APLS) pegcetacoplan posted mixed results in two Phase 3 trials in 1,258 geographic atrophy (GA). Despite the mixed... 
Via Benzinga
Exposures Product Safety
Where Apellis Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021
Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ: 
Via Benzinga
Recap: Apellis Pharmaceuticals Q2 Earnings
Shares of Apellis Pharmaceuticals (NASDAQ:APLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 73.25% year... 
Via Benzinga
Unusual Options Activity Insight: Apellis Pharmaceuticals
Shares of Apellis Pharmaceuticals (NASDAQ:APLS) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $65.4. Sentiment... 
Via Benzinga
10 Biggest Price Target Changes For Thursday
DA Davidson lowered the price target for WD-40 Company (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Credit Suisse raised the price target for Capital One Financial Corporation (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
Exposures Product Safety
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven... 
Via Benzinga
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers RAPT Therapeutics (NASDAQ:RAPT) s... 
Via Benzinga
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback